5Garces Jarque JM,Terradas Robledo R,Alvarez-Lerma F,et al.Lung aspergillosis.Role of the corticoids as associated risk factor in the patient with chronic bronchitis[J].Rev Clin Esp.2003,203(10):472-474.
6Ebiary M,Torres A,Fabregas N,et al.Significance of the isolation of Candida species from respiratory samples incritically ill nonneutropenic patients.Animmediate postmortem histologic study[J].Am J Resp it Crit Care Med,1997,156(2 pt 1):583-590.
7Rello J,Esandi M,Diaz E,et al.The role of Candida speciesisolated from bronchoscopic samples in nonneutropenic patients[J].Chest,1998,114(1):146-149.
3Stevens DA,Kan VL,Judson MA,et al.Practice guidelines for diseases caused by Aspergillus.Infectious Diseases Society of America.Clin Infect Dis,2000,30:696-709.
4Ascioglu S,Rex JH,de Pauw B,et al.Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants:an international consensus.Clin Infect Dis,2002,34:7-14.
5Denning DW,Kibbler CC,Barnes RA,et al.British Society for Medical Mycology proposed standards of care for patients with invasive fungal infections.Lancet Infect Dis,2003,3:230-240.
6Pappas PG,Rex JH,Sobel JD,et al.Guidelines for treatment of candidiasis.Clin Infect Dis,2004,38:161-189.
7Slavin MA,Szer J,Grigg AP,et al.Guidelines for the use of antifungal agents in the treatment of invasive Candida and mould infections.Intern Med J,2004,34:192-200.
8Saag MS,Graybill RJ,Larsen RA,et al.Practice guidelines for the management of cryptococcal disease.Infectious Diseases Society of America.Clin Infect Dis,2000,30:710-718.
9GOLD Executive Committee[DB/OL].Guidelines:Global Strategy for Diagnosis,Management,and Prevention of COPD,November 2006[2006-11-18].http://www.goldcopd.com/Guidelineitem.asp? l1 =2-12 = 1&intId =989.
10Celli BR,MacNee W,Committee members.Standard for the diagnosis and treatment of patients with COPD:a summary of the ATS/ERS position paper.Eur Respir J,2004,23:932-946.
